pregabalin + Placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Neuralgia

Conditions

Neuralgia

Trial Timeline

Jan 1, 2006 → May 1, 2008

NCT ID

NCT00292188

About pregabalin + Placebo

pregabalin + Placebo is a approved stage product being developed by Pfizer for Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00292188. Target conditions include Neuralgia.

What happened to similar drugs?

7 of 17 similar drugs in Neuralgia were approved

Approved (7) Terminated (3) Active (8)

✅QUTENZAAstellas PharmaApproved

✅GalcanezumabEli LillyApproved

✅Etoricoxib + PlaceboMerckApproved

✅pregabalinPfizerApproved

✅Lyrica (pregabalin) + PlaceboPfizerApproved

✅PregabalinPfizerApproved

✅pregabalinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03407430	Phase 2	Terminated	Jan 27, 2016	Jul 20, 2017	Breast Cancer
NCT02607254	Phase 2	Completed	Sep 1, 2015	Jul 1, 2018	Idiopathic Small Fiber Neuropathy
NCT01701362	Phase 3	Completed	Oct 1, 2012	Aug 1, 2015	Neuropathic Pain
NCT01387607	Phase 3	Completed	Feb 6, 2012	Oct 31, 2016	Fibromyalgia
NCT01455415	Phase 3	Completed	Dec 1, 2011	Dec 1, 2013	Painful Diabetic Peripheral Neuropathy
NCT01432236	Phase 3	Completed	Oct 1, 2011	Jul 1, 2013	Fibromyalgia
NCT01271660	Phase 3	Completed	Jul 1, 2011	Mar 1, 2018	Muscle Cramp
NCT01271933	Phase 3	Completed	Mar 1, 2011	Jul 1, 2012	Fibromyalgia
NCT01270828	Phase 3	Completed	Mar 1, 2011	Nov 1, 2014	Post Herpetic Neuralgia
NCT01049217	Phase 3	Terminated	Apr 1, 2010	May 1, 2012	Neuropathy
NCT00977197	Phase 2	Completed	Mar 1, 2010	Jun 1, 2015	Irritable Bowel Syndrome
NCT00883740	Phase 3	Completed	Jun 1, 2009	Jun 1, 2010	Fibromyalgia
NCT00762099	Approved	UNKNOWN	May 1, 2009	Dec 1, 2011	Anxiety
NCT00852436	Phase 2	Terminated	Feb 1, 2009	Oct 1, 2010	Neuropathic Pain
NCT00994786	Approved	Completed	Jan 1, 2009	Jan 1, 2019	Obsessive-Compulsive Disorder
NCT00631696	Approved	Completed	Feb 1, 2008	Feb 1, 2012	Healthy
NCT00584376	Approved	Completed	Dec 1, 2007	Nov 1, 2010	Essential Tremor
NCT00380874	Approved	Terminated	Jan 1, 2007	Mar 1, 2008	Chemotherapy-Induced Peripheral Neuropathy
NCT00381095	Approved	Terminated	Dec 1, 2006	Oct 1, 2010	Bone Neoplasms
NCT00413010	Phase 3	Completed	Dec 1, 2006	Mar 1, 2008	Generalized Anxiety Disorder

Competing Products

20 competing products in Neuralgia

See all competitors

Product	Company	Stage	Hype Score
Placebo + DS-5565	Daiichi Sankyo	Pre-clinical	26
QUTENZA	Astellas Pharma	Approved	43
ASP8477 + Placebo	Astellas Pharma	Phase 2	35
E2007 (perampanel) + Placebo	Eisai	Phase 2	35
E2007	Eisai	Phase 2/3	38
KHK6188 + Placebo	Kyowa Kirin	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Galcanezumab	Eli Lilly	Approved	43
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day	Jiangsu Hengrui Medicine	Phase 3	36
ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine	AbbVie	Phase 2	35
MK-8291 + Placebo	Merck	Phase 1	29
Etoricoxib + Placebo	Merck	Approved	39
Cetuximab + Placebo	Merck	Phase 2	35
ADL5747 + Placebo + Pregabalin	Merck	Phase 2	27
MK0759	Merck	Phase 2	27
MK0686	Merck	Phase 2	27
Comparator: pregabalin + Comparator: Placebo (unspecified)	Merck	Phase 1	29
EMA401 + Placebo	Novartis	Phase 2	27
pregabalin	Pfizer	Approved	43
Lyrica (pregabalin) + Placebo	Pfizer	Approved	43